Business
Ventripoint to Exhibit at the American College of Cardiology 71st Annual Scientific Session and Expo and Correction to North Equities Corp Grant of Stock Options
(TheNewswire) Toronto, Ontario – TheNewswire – April 1, 2022 ...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint to Exhibit at the American College of Cardiology 71st Annual Scientific Session and Expo and Correction to North Equities Corp Grant of Stock Options\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Toronto, Ontario – TheNewswire\n– April 1, 2022\n \n \n -\n \n \n Ventripoint Diagnostics Ltd\n \n \n . (\"\n \n \n Ventripoint\n \n \n \" or the \"\n \n \n Company\n \n \n \"),\n(TSXV:VPT\n \n \n )\n \n \n ;\n \n \n (\n \n \n OTC:VPTDF) is pleased to announce that\nit will be exhibiting at the 71st Annual Scientific Session and Expo,\nhosted by the American College of Cardiology (ACC) between April 2-4,\n2022, in Washington, D.C, United States.\n \n \n \n \n The ACC is a not-for-profit medical community that has\nover 54,000 medical professionals worldwide. The ACC aims to provide\nthe best care possible for patients with cardiovascular disease and to\nhelp raise awareness about the prevention of cardiovascular disease.\n \n \n \n \n The conference will be highlighting the latest\nadvancements in cardiac care and will be holding specific education\nsessions for practitioner continuing education. Some of the keynote\ntopics will include health equity in cardiovascular disease\nprevention, technology, heart healthy diet, and more.  The conference\nalready has over 18,000 members attending and will provide an\nexcellent opportunity for Ventripoint to connect with the\ncardiovascular community and engage in pressing topics within the\nfield.\n \n \n \n \n Additionally, Ventripoint would like to correct the\npress release dated March 2, 2022, regarding options for marketing\nfirm North Equities Corp.  The Company has granted an aggregate of\n660,000 stock options with an exercise price of $0.33 per share\nexercisable for a period of two years vesting quarterly in accordance\nwith TSXV policies.\n \n \n \n \n About Ventripoint Diagnostics\nLtd.\n \n \n \n \n Ventripoint\n \n \n has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary KBR technology, which is the result of a decade of\ndevelopment and provides accurate volumetric cardiac measurements\nequivalent to MRI. This affordable, gold-standard alternative allows\ncardiologists greater confidence in the management of their patients.\nProviding b...